References
- Poesen , Van Damme. Front Neurol. 2019;9:1167.
- Gotkine M, Schoenfeld D, CohenI, et al. Poster presented at Virtual 33rd International Symposium on ALS/MND (Northampton), 2022.
References
- Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109–19.
- Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–110.
- Meyer T, Schumann P, Weydt P, et al. Neurofilament light-chain response during therapy with antisense oligonucleotide Tofersen in SOD1-related ALS: treatment experience in clinical practice. Muscle Nerve. 2023;67(6):515–21.
References
- Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363–80.
- Hooten KG, Beers DR, Zhao W, et al. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):364–75.
References
- Banack SA, Dunlop RA, Cox PA. Open Biol. 2020;10:200116.
- Banack SA, Dunlop RA, Stommel EW, et al. J Neurol Sci. 2022;442:120396.
References
- Gagliardi S, Zucca S, Pandini C. et al Long non-coding and coding RNAs characterization in peripheral blood mononuclear cells and spinal cord from amyotrophic lateral sclerosis patients. Sci Rep. 2018;8(1):2378.
- Sproviero D, Gagliardi S, Zucca S. et al. Different miRNA profiles in plasma derived small and large extracellular vesicles from patients with neurodegenerative diseases. Int J Mol Sci. 2021;22(5):2737.
References
- Dupuis L, Petersen Å, Weydt P. Handb Clin Neurol. 2018;157;749–60.
- Dupuis L, Pradat P-F, Ludolph AC, et al. 2011;10;75–82.
- Marlatt KL, Ravussin E. Curr Obes Rep. 2017;6, 389–96.
- Aquilano K, Sciarretta F, Turchi R. et al. Redox Biol. 2020;36:101633.
- Rosina M, Ceci V, Turchi R. et al. Cell Metab. 2022;34;533–548.e12.
Reference
- Winter B, Guenther R, Ludolph AC et al. Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. Journal of neurology, neurosurgery, and psychiatry. 2019;90(9):1068–9.
References
- Chen HJ, Mitchell JC, Novoselov S, et al. The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. Brain. 2016;139(5):1417–1432.
- Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416–438.
- Carrasco J, Antón R, Valbuena A, et al. Metamorphism in TDP-43 prion-like domain determines chaperone recognition. Nat Commun. 2023;14(1):466.
- Park SK, Arslan F, Kanneganti V, et al. Overexpression of a conserved HSP40 chaperone reduces toxicity of several neurodegenerative disease proteins. Prion. 2018;12(1):16–22.
References
- Caggiano C, Celona B, Garton F, et al. Comprehensive cell type decomposition of circulating cell-free DNA with CelFiE. Nature Communications 2021;12(2717).
- Farrell C, Thompson M, Tosevska A, et al. BiSulfite Bolt: a bisulfite sequencing analysis platform. Gigascience. 2021;10(5):giab033.
References
- Beland LC, Markovinovic A, Jakovac H. et al. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient brain responses. Brain Commun. 2020;2(2):fcaa124.
- George L, Brightling CE. et al. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Therapeutic Advances in Chronic Disease. 2016;7(1):34–51
- Sakin A, Secmeler S, Arici S. et al. Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy, Sci Rep. 2019;9(1):3959
- Ulasli SS, Ozyurek BA, Yilmaz EB. et al. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012;122(6):284–90.